FBXL5 and myelodysplastic syndrome: Suppression of IRP2 activity in FBXL5-deficient HSCs restored stem cell function, implicating IRP2 as a potential novel therapeutic target in stem cell diseases such as MDS that are associated with cellular iron overload.